Holocene Advisors LP acquired a new stake in shares of MetLife, Inc. (NYSE:MET - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 52,802 shares of the financial services provider's stock, valued at approximately $4,355,000.
A number of other hedge funds have also recently bought and sold shares of the business. Community Bank N.A. grew its position in shares of MetLife by 205.7% in the 3rd quarter. Community Bank N.A. now owns 8,054 shares of the financial services provider's stock worth $664,000 after acquiring an additional 5,419 shares in the last quarter. Benjamin Edwards Inc. grew its position in shares of MetLife by 556.9% in the 3rd quarter. Benjamin Edwards Inc. now owns 15,910 shares of the financial services provider's stock worth $1,313,000 after acquiring an additional 13,488 shares in the last quarter. Atom Investors LP acquired a new position in shares of MetLife in the 3rd quarter worth approximately $358,000. Kestra Investment Management LLC acquired a new position in shares of MetLife in the 3rd quarter worth approximately $232,000. Finally, Paradigm Capital Management LLC NV acquired a new position in shares of MetLife in the 3rd quarter worth approximately $1,226,000. Institutional investors and hedge funds own 89.81% of the company's stock.
Shares of MetLife stock opened at $85.35 on Thursday. The business's fifty day moving average price is $83.65 and its two-hundred day moving average price is $76.85. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.16 and a quick ratio of 0.16. The company has a market capitalization of $59.10 billion, a P/E ratio of 17.21, a PEG ratio of 0.80 and a beta of 1.06. MetLife, Inc. has a 1-year low of $63.19 and a 1-year high of $89.05.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Tuesday, November 5th will be paid a dividend of $0.545 per share. This represents a $2.18 annualized dividend and a yield of 2.55%. The ex-dividend date is Tuesday, November 5th. MetLife's payout ratio is currently 43.95%.
Several research analysts have recently commented on MET shares. Piper Sandler lifted their target price on MetLife from $85.00 to $92.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 2nd. Jefferies Financial Group lifted their target price on MetLife from $89.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, September 27th. TD Cowen raised their price target on MetLife from $97.00 to $99.00 and gave the stock a "buy" rating in a report on Wednesday, November 27th. Barclays cut their price target on MetLife from $91.00 to $90.00 and set an "overweight" rating on the stock in a report on Thursday, October 31st. Finally, Morgan Stanley cut their price target on MetLife from $86.00 to $85.00 and set an "overweight" rating on the stock in a report on Monday, August 19th. Fourteen investment analysts have rated the stock with a buy rating, According to MarketBeat, MetLife currently has a consensus rating of "Buy" and a consensus target price of $88.62.
Read Our Latest Stock Analysis on MetLife
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.